Inozyme Pharma, Inc. (INZY)

4,7400 +0,0900 (+1,94%) Börsenschluss: 04:00PM EDT

Inozyme Pharma, Inc.

321 Summer Street
Suite 400
Boston, MA 02210
United States
(857) 330-4340
https://www.inozyme.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 59

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Dr. Douglas A. Treco Ph.D.	CEO & Chairman	591,88k	N/A	1958
Mr. Axel Bolte M.B.A., M.Sc.	Co-Founder, Senior Advisor & Director	1,16M	N/A	1972
Mr. Sanjay S. Subramanian M.B.A., M.S.	Senior VP, CFO, Principal Accounting Officer & Corporate Secretary	626,23k	N/A	1977
Dr. Matthew Winton Ph.D.	Senior VP & COO	526,43k	N/A	1978
Dr. Demetrios Braddock M.D., Ph.D.	Co-Founder, Scientific Founder, Member of Scientific Advisory Board & Board Observer	N/A	N/A	N/A
Dr. Soojin Kim Ph.D.	Senior VP & Chief Technical Operations Officer	N/A	N/A	N/A
Dr. David Thompson M.A., M.S., Ph.D.	Senior VP, Chief Scientific Officer & Chief Development Officer	N/A	N/A	N/A
Mr. Stefan Riley	Director of Investor Relations	N/A	N/A	N/A
Ms. Gayle Gironda	Senior VP & Chief People Officer	N/A	N/A	N/A
Dr. Yves Sabbagh Ph.D.	Chairman of Scientific Advisory Board & Senior VP	N/A	N/A	N/A

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

Inozyme Pharma, Inc., a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.

Corporate Governance

Inozyme Pharma, Inc.s ISS Governance QualityScore, Stand 1. Mai 2024, lautet 8. Die grundlegenden Scores sind Audit: 9, Vorstand: 9, Shareholderrechte: 8, Kompensation: 8.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.